Taiho Pharmaceutical, the wholly owned Otsuka Holdings subsidiary, said its experimental lung cancer drug zipalertinib cleared a planned interim checkpoint in a global Phase III trial, hitting the study's main goal of extending progression-free survival when paired with chemotherapy. The independent data monitoring committee overseeing the trial recommended unblinding it once the results came in, and the company says the improvement was both statistically significant and clinically meaningful, with manageable safety in the combination arm.
The trial, called REZILIENT3, is a multicenter, randomized, open-label study that enrolled 285 adults with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer carrying an EGFR exon 20 insertion mutation, a genetic subtype that has historically had fewer targeted first-line options. It compares zipalertinib plus platinum-based chemotherapy against chemotherapy alone as initial treatment. Taiho developed zipalertinib in-house (development code CLN-081/TAS6417) and runs the program through its US subsidiary Taiho Oncology, working in the United States alongside Nasdaq-listed Cullinan Therapeutics.
Exon 20 insertion mutations are a narrow but persistent problem in lung oncology. Taiho cites published literature putting the mutation's global prevalence at up to 4% of non-small cell lung cancer cases; in the United States, roughly 16% of such patients carry any EGFR mutation, and exon 20 insertions account for up to 12% of that EGFR-mutated group. That is a small slice of a large disease, which is exactly the kind of segment drugmakers chase when broader EGFR inhibitors do not cover it.
Taiho Oncology's global chief medical officer, Fabio Benedetti, called the result an important milestone for the program, and executives at both Taiho Oncology and Cullinan Therapeutics framed the data as support for using the combination as a first-line therapy rather than a later-line rescue option. The three companies now plan detailed results for a future medical conference and intend to consult the US Food and Drug Administration on pursuing approval of the combination as a first-line treatment.
None of that has changed Otsuka's numbers yet. The parent company said its consolidated earnings forecast for the year ending December 2026 is unchanged, even as it flagged zipalertinib as one of the products it expects to drive future growth. Zipalertinib remains unapproved by any drug regulator worldwide, and the interim analysis, while positive, is not the same as a completed trial readout or a regulatory filing. The companies have not yet disclosed the magnitude of the survival benefit, only that it cleared the study's statistical bar.